Neurodevelopmental Disorders Clinical Trials Centre (NDD-CTC)
Aims
We undertake clinical trials for the core symptoms and associated conditions of neurodevelopmental disorders in collaboration with industry partners, King’s clinical trials unit, KHP clinical trials office, the NIHR Maudsley Biomedical Research Centre and the NIHR / Wellcome Trust King's Clinical Research Facility.
Our focus
The NDD-CTC undertakes fully powered clinical trials of potential treatments identified in our clinical trials pipeline based on shiftability and other experimental studies within the department, and includes treatments for individuals with Autism spectrum conditions, Down syndrome, and intellectual disabilities.
Our Process
 |
Step 1: Find biomarker of neurodevelopmental disorder or comorbid condition shared by a group of people |
 |
Step 2: Conduct 'shiftability study': target biomarker with dose of compound to test for response on biomarker |
 |
Step 3: Does this make a biological difference? NO - STOP |
 |
Step 4: Yes - move forward to 'Fast Fail' trial |
 |
Conduct 'Fast Fail' trial to test if we can maintain shift in the biomarker for ~weeks |
 |
Yes - full clinical trial should be done in people we know should respond |
 |
Step 7: |
Our Partners
NIHR Maudsley Biomedical Research Centre
Principal Investigator
Professor in Intellectual Disabilities
Investigators
Professor of Psychiatry and Brain Maturation
Professor of Translational Neuroscience